ctrlnum article-412
fullrecord <?xml version="1.0"?> <dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><title lang="id-ID">STUDI PERBANDINGAN PENGOBATAN HALOFANTRIN ANTARA PENDERITA MALARIA FALSIPARUM TANPA KOMPLIKASI YANG IN VITRO SENSITIF DENGAN YANG RESISTEN KLOROKUIN</title><creator>Tjitra, Emiliana; Badan Penelitian dan Pengembangan Kesehatan, Depkes RI</creator><creator>Oemijati, Sri; Bagian Parasitologi, FKUI, Jakarta</creator><creator>Pribadi, Wita; Bagian Parasitologi, FKUI, Jakarta</creator><creator>Arbadi, P. R.; Direktorat Jenderal PPM-PLP, Departemen Kesehatan RI</creator><creator>Romzan, Ali; Direktorat Jenderal PPM-PLP, Departemen Kesehatan RI</creator><creator>Renny, Marvel; Badan Penelitian dan Pengembangan Kesehatan, Depkes RI</creator><creator>Marwoto, Hariyani; Badan Penelitian dan Pengembangan Kesehatan, Depkes RI</creator><subject lang="id-ID">Health; Kesehatan</subject><subject lang="id-ID">Falciparum Malaria; Halofantrine; Chloroquine</subject><subject lang="id-ID"/><description lang="id-ID">Halofantrine study on uncomplicated falciparum malaria patients was carried out at ITCI hospital in Balikpapan, East Kalimantan, Indonesia in 1990-1991. This study was conducted to compare the efficacy and safety of halofantrine on in vitro sensitive and resistant chloroquine falciparum malaria patients. Of the 80 patients selected according to WHO criteria for in vivo and in vitro drug sensitivity test and treated orally with 500 mg halofantrine 6 hourly for 3 doses, only 46 patients could be further analized as the in vitro sensitive group (19) and resistant group (27). On admission, no significant different findings were noted in characteristics, clinical symptoms and signs, hematological and biochemical parameters between the sensitive and resistant groups except thrombocyte and creatinine. Clinical symptoms more frequently encountered were headache (92,6-100%), fever (789- 92,6%), chills (78,9-85,2%) and nausea or/and vomiting (57,9-63%). There were no significant differences between the sensitive and resistant groups in cure rate (100% and 96,3%), fever clearance time (17,1 &#xB1; 3,5 h and 21,8 &#xB1; 4,6 h) and parasite clearance time (51,6 &#xB1; 2,8 h and 66,9 &#xB1;&#xA0;12,1 h). When the patients were discharged, the hematological and biochemical parameters showed normal values, except thrombocyte, but the differences between those groups were insignificant. This study showed that halofantrine is effective and safe both for treatment on in vitro sensitive chloroquine falciparum malaria patients and for treatment on in vitro resistant chloroquine falciparum malaria patients.</description><publisher lang="en-US">Badan Penelitian dan Pengembangan Kesehatan</publisher><contributor lang="id-ID">BADAN LITBANGKES KEMENKES</contributor><date>2012-09-11</date><type>Other:</type><type>File:application/pdf</type><identifier>http://ejournal.litbang.depkes.go.id/index.php/BPK/article/view/412</identifier><source lang="id-ID">Buletin Penelitian Kesehatan; Vol 21, No 1 Mar (1993)</source><source lang="en-US">Buletin Penelitian Kesehatan; Vol 21, No 1 Mar (1993)</source><language>ind</language><rights>The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Buletin Penelitian Kesehatan (Bulletin of Health Research) and Badan Penelitian dan Pengembangan Kesehatan (National Institute of Health Research and Development) as publisher of the journal.Copyright encompasses exclusive rights to reproduce and deliver the article in all form and media, including reprints, photographs, microfilms and any other similar reproductions, as well as translations. The reproduction of any part of this journal, its storage in databases and its transmission by any form or media, such as electronic, electrostatic and mechanical copies, photocopies, recordings, magnetic media, etc. , will be allowed only with a written permission from Buletin Penelitian Kesehatan (Bulletin of Health Research) and Badan Penelitian dan Pengembangan Kesehatan (National Institute of Health Research and Development).Buletin Penelitian Kesehatan (Bulletin of Health Research) and Badan Penelitian dan Pengembangan Kesehatan (National Institute of Health Research and Development), the Editors and the Advisory International Editorial Board make every effort to ensure that no wrong or misleading data, opinions or statements be published in the journal.</rights><recordID>article-412</recordID></dc>
language ind
format Other:
Other
File:application/pdf
File
Journal:eJournal
Journal
author Tjitra, Emiliana; Badan Penelitian dan Pengembangan Kesehatan, Depkes RI
Oemijati, Sri; Bagian Parasitologi, FKUI, Jakarta
Pribadi, Wita; Bagian Parasitologi, FKUI, Jakarta
Arbadi, P. R.; Direktorat Jenderal PPM-PLP, Departemen Kesehatan RI
Romzan, Ali; Direktorat Jenderal PPM-PLP, Departemen Kesehatan RI
Renny, Marvel; Badan Penelitian dan Pengembangan Kesehatan, Depkes RI
Marwoto, Hariyani; Badan Penelitian dan Pengembangan Kesehatan, Depkes RI
author2 BADAN LITBANGKES KEMENKES
title STUDI PERBANDINGAN PENGOBATAN HALOFANTRIN ANTARA PENDERITA MALARIA FALSIPARUM TANPA KOMPLIKASI YANG IN VITRO SENSITIF DENGAN YANG RESISTEN KLOROKUIN
publisher Badan Penelitian dan Pengembangan Kesehatan
publishDate 2012
topic Health
Kesehatan
Falciparum Malaria
Halofantrine
Chloroquine
url http://ejournal.litbang.depkes.go.id/index.php/BPK/article/view/412
contents Halofantrine study on uncomplicated falciparum malaria patients was carried out at ITCI hospital in Balikpapan, East Kalimantan, Indonesia in 1990-1991. This study was conducted to compare the efficacy and safety of halofantrine on in vitro sensitive and resistant chloroquine falciparum malaria patients. Of the 80 patients selected according to WHO criteria for in vivo and in vitro drug sensitivity test and treated orally with 500 mg halofantrine 6 hourly for 3 doses, only 46 patients could be further analized as the in vitro sensitive group (19) and resistant group (27). On admission, no significant different findings were noted in characteristics, clinical symptoms and signs, hematological and biochemical parameters between the sensitive and resistant groups except thrombocyte and creatinine. Clinical symptoms more frequently encountered were headache (92,6-100%), fever (789- 92,6%), chills (78,9-85,2%) and nausea or/and vomiting (57,9-63%). There were no significant differences between the sensitive and resistant groups in cure rate (100% and 96,3%), fever clearance time (17,1 ± 3,5 h and 21,8 ± 4,6 h) and parasite clearance time (51,6 ± 2,8 h and 66,9 ± 12,1 h). When the patients were discharged, the hematological and biochemical parameters showed normal values, except thrombocyte, but the differences between those groups were insignificant. This study showed that halofantrine is effective and safe both for treatment on in vitro sensitive chloroquine falciparum malaria patients and for treatment on in vitro resistant chloroquine falciparum malaria patients.
id IOS13.article-412
institution Badan Penelitian dan Pengembangan Kesehatan
affiliation onesearch.kink.kemkes.go.id
hellis.onesearch.id
institution_id 12
institution_type library:special
library
library Perpustakaan Badan Penelitian dan Pengembangan Kesehatan
library_id 16
collection Buletin Penelitian Kesehatan
repository_id 13
subject_area Kesehatan dan Kedokteran
city JAKARTA PUSAT
province DKI JAKARTA
repoId IOS13
first_indexed 2016-09-16T12:27:16Z
last_indexed 2016-09-24T06:27:21Z
recordtype dc
merged_child_boolean 1
_version_ 1722421399167959040
score 17.611881